We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) and LEO Pharma A/S ("LEO") have entered into a collaboration agreement to develop and market ATryn(R) for markets in Europe, the Middle East, and Canada.
The Kenyan government has announced that it will not intervene in the increasingly bitter dispute between international drugmakers in the country and freelance drug importers
Jamaica's National Health Fund (NHF) is to subsidise up to 80% of the cost of diabetes treatments in a move that will cost an estimated US$495mn per year.
Industry sources in Pakistan fear that the increasing competition from India and China could force 60% of the country's domestic drugmakers out of business within the next two to three years, and have called for government action to help reverse this worrying trend.
Generic drug company Hikma Pharmaceuticals said on Monday it planned to float on the London Stock Exchange with a price range of 265 to 330 pence, the middle of which values it at about 500 million pounds ($874.9 million).
What's not to like about this pharmaceutical outfit's brimming pipeline, locked-in market, and what S&P sees as its undervalued stock? As the population ages, we expect an increase in demand for pain-management therapies for both chronic conditions and surgical procedures.
Biotech Holdings (the "Company", BIO: TSX.V, BIOHF: OTCBB), announced that sales (in Cdn $ unless otherwise specified) in the Company's second quarter, ended September 30, 2005, totaled $211,654 ($173,864 US), compared to sales of $123,411 ($99,904 US) in the quarter ended June 30, 2005.